Cancer vaccines poised to unlock 'new treatment paradigm' wi

CHICAGO (Reuters) - Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. | 08:21am

Related Keywords

New York , United States , Chicago , Illinois , American , Jane Healy , Vinod Balachandran , Julie Steenhuysen , Merck Moderna , Caroline Humer , Merck Keytruda , Roche Tecentriq , Andrew Allen , Gritstone Bio Inc , Researchers At Memorial Sloan Kettering Cancer Center , American Society Of Clinical Oncology , American Society , Clinical Oncology , Memorial Sloan Kettering Cancer Center , Bill Berkrot , ,